IQVIA (NYSE:IQV) Rating Lowered to “Neutral” at BTIG Research

IQVIA (NYSE:IQV) was downgraded by BTIG Research from a “buy” rating to a “neutral” rating in a report released on Monday, Marketbeat Ratings reports.

Several other equities analysts have also weighed in on the company. Truist Financial decreased their target price on IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a research report on Thursday, December 12th. Redburn Atlantic initiated coverage on IQVIA in a research note on Monday, October 14th. They set a “buy” rating and a $276.00 price target for the company. Leerink Partners reaffirmed an “outperform” rating and set a $248.00 target price (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Deutsche Bank Aktiengesellschaft dropped their price objective on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Finally, Robert W. Baird decreased their target price on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, January 21st. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and a consensus target price of $255.71.

IQVIA Trading Down 0.2 %

Shares of NYSE IQV opened at $201.34 on Monday. The stock has a market cap of $36.54 billion, a P/E ratio of 26.42, a price-to-earnings-growth ratio of 2.15 and a beta of 1.48. IQVIA has a 52-week low of $187.62 and a 52-week high of $261.73. The firm has a 50 day moving average price of $200.41 and a two-hundred day moving average price of $220.32. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of IQV. Capital Performance Advisors LLP acquired a new stake in IQVIA during the third quarter worth approximately $27,000. Park Place Capital Corp purchased a new stake in IQVIA during the 3rd quarter worth $28,000. Synergy Asset Management LLC acquired a new stake in shares of IQVIA in the fourth quarter valued at about $33,000. Avior Wealth Management LLC lifted its position in IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after acquiring an additional 87 shares in the last quarter. Finally, Assetmark Inc. grew its position in IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 196 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.